PR Newswire
01 Jun 2023, 17:30 GMT+10
MELBOURNE, Australia, June 1, 2023 /PRNewswire/ -- The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted under a U.S. FDA Investigational New Drug Application.
Allergy clinical trial centres across Victoria, South Australia, New South Wales, and Western Australia have invited children and adolescents aged four to 17 years with peanut allergy to take part in the Phase 2 study. Researchers aim to evaluate the efficacy of the novel therapy PVX108.
In Phase 1 trials, researchers observed that PVX108 produced relevant changes in the immune response to peanut protein, which continued to develop once dosing had completed.
"We're thrilled to have dosed our first patient in Phase 2. In this Phase 2 trial we will evaluate how the immunological changes observed in Phase 1 trials translate to clinical reductions in allergic reactivity and the development of tolerance to peanuts following 12 monthly doses of PVX108," says Dr Pascal Hickey, CEO, Aravax.
Unlike most treatments available or under development for peanut allergy, Aravax's PVX108 does not contain peanut proteins which put patients at risk of serious side effects. Aravax is applying its platform technology to develop specific immunotherapies for food allergies which are designed to precisely retrain the immune system to tolerate peanut allergens.
These therapies are anticipated to be highly differentiated based on greatly improved safety profile, and the potential for sustained clinical benefits possibly leading to reversal of allergic disease.
Clinical trial AVX-201 is led in Australia by regional principal investigator Associate Professor Kirsten Perrett, Population Allergy Group Leader at the Murdoch Children's Research Institute. Associate Professor Perrett is also a Paediatric Allergist and Vaccinologist and Director of the National Allergy Centre of Excellence (NACE).
Aravax will be attending BIO 2023 in Boston next week, and, Chief Scientific Officer Sara Prickett will be speaking at the European Academy of Allergy & Clinical Immunology Congress 2023 (Hamburg, 9-11 June), in a presentation titled: 'A Peptide Immunotherapy for Peanut Allergy Safely Induces Durable Immune Changes in Peanut-Allergic Adults'.
"I'm excited to be speaking at EAACI to some of the world's top immunology experts about the great progress being made at Aravax to tackle peanut allergies, an issue that affects millions of people globally. I've seen the impact that peanut allergies not only have on patients, but also families," Prickett says.
Aravax's Phase 2 trials of PVX108 follow on from $20m investment as part of its series B funding round, led by Australian life science investors, Brandon Capital and Tenmile.
More information and details on how to apply to participate in the clinical trial can be found on the on the NACE and Aravax websites.
CONTACT: Ciara Byrne, [email protected]
Get a daily dose of Singapore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.
More InformationWASHINGTON, D.C.: The United States has placed sanctions on two sons of jailed Mexican drug lord Joaquin El Chapo Guzman. These two...
LONDON, UK: Frederick Forsyth, the renowned British author behind The Day of the Jackal and numerous other bestselling thrillers, has...
PUERTO PRINCESA, Philippines: A Chinese ship got stuck in shallow waters near a Philippine-controlled island in the disputed South...
Nearly three months after a devastating earthquake struck Myanmar, the country remains trapped in a deepening crisis, compounded by...
HONG KONG: In a bid to tackle its declining birth rate, China will soon require all major hospitals to offer epidural anesthesia during...
WARSAW, Poland: Poland held a second round of voting in its presidential election on Sunday, but exit polls show the race is too close...
HARRISBURG, Pennsylvania: Amazon is making a significant play in Pennsylvania, announcing plans to pour at least US$20 billion into...
MUMBAI/LONDON: Fast-fashion giant Shein and India's Reliance Retail are preparing to transform India into a significant global supply...
BURBANK, California: Warner Bros Discovery is officially breaking itself in two. In a move that signals a major pivot for the media...
NEW YORK, New York - U.S. stocks closed modestly lower Wednesday despite a tentative trade agreement between the United States and...
Throughout human history, zoonotic diseases, illnesses that jump from animals to humans, have shaped civilizations, triggered pandemics,...
WASHINGTON, D.C.: A boom in U.S. solar energy installations may be running out of steam as shifting federal priorities, new tariffs,...